Research paperAdditive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein
References (36)
- et al.
Tumor necrosis factor-alpha enhances interferon-gamma-mediated class II antigen expression on astrocytes
J. Neuroimmunol.
(1989) - et al.
Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis
Lancet
(1986) - et al.
Interferon β-1b reduces interferon-γ-induced antigen presenting capacity of human glial and B cells
J. Neuroimmunol.
(1995) - et al.
Clinical trials of interferons in multiple sclerosis. What have we learned?
J. Neuroimmunol.
(1993) - et al.
Copolymer-1-induced inhibition of antigen-specific T-cell activation: interference with antigen presentation
J. Neuroimmunol.
(1992) - et al.
Clinical viral infections and multiple sclerosis
Lancet
(1985) - et al.
Rat ependyma and microglial cells express class II MHC antigens after intravenous infusion of recombinant gamma interferon
J. Neuroimmunol.
(1988) - et al.
Therapy of multiple sclerosis
Neurol. Clin.
(1995) - et al.
T-cell recognition of myelin basic protein
Immunol. Today
(1991) - et al.
T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer-1 or spinal cord homogenate downregulate experimental allergic encephalomyelitis
Eur. J. Immunol.
(1993)
T cells responsive to myelin basic protein in patients with multiple sclerosis
Science
Suppression of demyelinating disease by synthetic copolymers
A pilot trial of Cop 1 in exacerbating—remitting multiple sclerosis
N. Engl. J. Med.
Interferongamma regulates an antigen specific for endothelial cells involved in lymphocyte traffic
Direct binding of myelin basic protein and synthetic copolymer I to class II major histocompatibility complex molecules on living antigen presenting cells: specificity and promiscuity
Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis
Ann. Neurol.
Copolymer 1 (Cop I) reduces the relapse rate and progression of disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial
Neurology
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals
J. Immunol.
Cited by (57)
Interferon Beta and Glatiramer Acetate Therapy
2013, NeurotherapeuticsThe CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics
2012, Multiple Sclerosis and Related DisordersCitation Excerpt :In the CombiRx study, the two agents have multiple suggested mechanisms by which they might benefit MS, and it remains to be seen whether the combination will be additive, synergistic, or antagonistic. The pilot trial suggested that the combination would be safe and not antagonistic (Lublin et al., 2002), while in vitro and animal studies gave mixed results (Brod et al., 2000; Dhib-Jalbut et al., 2002; Milo and Panitch, 1995). In addition to concerns about the usefulness of combined IFNB and GA in RRMS, practical barriers also exist.
Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs
2011, Journal of NeuroimmunologyCitation Excerpt :Cultures of thyrocytes were treated for 24 h with IFNβ-1b (Extavia, Novartis International AG, Basel Switzerland) at the concentrations of 100, 500, 1000, 5000 U/ml and 10,000 U/ml, or GA (Teva-Pharmaceuticals Ind Ltd., Kfar Saba, Israel) at the concentrations of 5, 10, 20, 50 μg/ml. IFN-β and GA were used at concentration ranges reported to be bioactive and not toxic for cultured human cells (Milo and Panitch, 1995; Li et al., 1998). Given the previously reported synergy between IFN-γ and TNF-α in promoting inflammatory responses (Ohmori et al., 1997), the experiments were performed by using IFN-β and GA both alone or in combinations with 10 ng/ml TNF-α (R&D Systems, Minneapolis, MN, USA).
Combination therapy in multiple sclerosis
2011, Journal of NeuroimmunologyCitation Excerpt :These effects were reduced or minimal with either drug alone in this setting (Paintlia et al., 2008). In contrast to the in-vitro additive effects of IFNβ and GA on the T-cell response to MBP (Milo and Panitch, 1995), the combination of oral or parenteral interferon alpha (another type-I IFN with similar effects on the immune system) and GA was counterproductive in suppressing EAE while being effective when used alone (Brod et al., 2000). These results suggest possible antagonistic rather than synergistic effects of interferons and GA in-vivo and raise concerns for the safety of the combination.
MS treatment: New perspectives
2006, Clinical Neurology and NeurosurgeryGlatiramer acetate in the treatment of multiple sclerosis
2005, Neurologic ClinicsCitation Excerpt :Experimental investigations in vitro show conflicting effects. Milo and Panitch [28] found additive effects of GA and IFN-β1b on the suppression of proliferation of MBP-specific T-cell lines. In contrast, Zang et al, found that IFN-β antagonized the effects of GA on the induction of activation and cytokine production of T cells [29].
- 1
Present address: Department of Neurology, Assaf Harofeh Medical Center, Zerifin 70300, Israel.